Can I read Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands on EtoBox?

Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands by Meijer, Rick I. (author);Hoekstra, Trynke (author);van den Oever, Niels C. Gritters (author);Simsek, Suat (author);van den Bergh, Joop P. (author);Douma, Renée A. (author);Reidinga, Auke C. (author);Moeniralam, Hazra S. (author);Dormans, Tom (author);, Amsterdam UMC COVID-19 biobank study group (author);Smits, Mark M. (author) is a Medicine article available to read on EtoBox.

What is Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands about?

## Purpose Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. ## Methods We studied in 565 patients with type 2 diabetes in the CovidPredict Clinical Course Cohort whether use of a DPP-4 inhibitor prior to hospital admission due to COVID-19 was associated with improved clinical outcomes. Using crude analyses and propensity score matching (on age, sex and BMI), 28 patients using a DPP-4 inhibitor were identified and compared to non-users. ## Results No differences were found in the primary outcome mortality (matched-analysis = odds-ratio: 0,94 [95% confidence interval: 0,69 – 1,28], __p__-value: 0,689) or any of the secondary outcomes (ICU admission, invasive ventilation, thrombotic events or infectious complications). Additional analyses comparing users of DPP-4 inhibitors with subgroups of non-users (subgroup 1: users of metformin and sulphonylurea; subgroup 2: users of any insulin combination), allowing to correct for diabetes severity, did not yield different results. ## Conclusions We conclude that

Who reads Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands?

Author

Meijer, Rick I. (author);Hoekstra, Trynke (author);van den Oever, Niels C. Gritters (author);Simsek, Suat (author);van den Bergh, Joop P. (author);Douma, Renée A. (author);Reidinga, Auke C. (author);Moeniralam, Hazra S. (author);Dormans, Tom (author);, Amsterdam UMC COVID-19 biobank study group (author);Smits, Mark M. (author)

Publisher

Springer Science and Business Media LLC

Published

2021

Language

EN

Field

Medicine (Health Sciences)